vs
Side-by-side financial comparison of SOLENO THERAPEUTICS INC (SLNO) and TSS, Inc. (TSSI). Click either name above to swap in a different company.
SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $60.9M, roughly 1.1× TSS, Inc.). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs 20.0%, a 19.4% gap on every dollar of revenue. SOLENO THERAPEUTICS INC produced more free cash flow last quarter ($43.5M vs $15.8M).
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
SLNO vs TSSI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $66.0M | $60.9M |
| Net Profit | $26.0M | $12.2M |
| Gross Margin | 98.3% | 17.6% |
| Operating Margin | 33.5% | 1.5% |
| Net Margin | 39.4% | 20.0% |
| Revenue YoY | — | 21.8% |
| Net Profit YoY | 134.0% | 535.7% |
| EPS (diluted) | $0.47 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $60.9M | ||
| Q3 25 | $66.0M | $41.9M | ||
| Q2 25 | $32.7M | $44.0M | ||
| Q1 25 | — | $99.0M | ||
| Q4 24 | — | $50.0M | ||
| Q3 24 | — | $70.1M | ||
| Q2 24 | — | $12.2M | ||
| Q1 24 | — | $15.9M |
| Q4 25 | — | $12.2M | ||
| Q3 25 | $26.0M | $-1.5M | ||
| Q2 25 | $-4.7M | $1.5M | ||
| Q1 25 | — | $3.0M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | — | $2.6M | ||
| Q2 24 | — | $1.4M | ||
| Q1 24 | — | $15.0K |
| Q4 25 | — | 17.6% | ||
| Q3 25 | 98.3% | 11.1% | ||
| Q2 25 | 97.9% | 17.8% | ||
| Q1 25 | — | 9.3% | ||
| Q4 24 | — | 14.4% | ||
| Q3 24 | — | 11.3% | ||
| Q2 24 | — | 37.3% | ||
| Q1 24 | — | 17.1% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | 33.5% | -2.2% | ||
| Q2 25 | -20.0% | 5.1% | ||
| Q1 25 | — | 4.2% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 5.4% | ||
| Q2 24 | — | 14.0% | ||
| Q1 24 | — | 1.6% |
| Q4 25 | — | 20.0% | ||
| Q3 25 | 39.4% | -3.6% | ||
| Q2 25 | -14.4% | 3.4% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 3.8% | ||
| Q2 24 | — | 11.5% | ||
| Q1 24 | — | 0.1% |
| Q4 25 | — | $0.44 | ||
| Q3 25 | $0.47 | $-0.06 | ||
| Q2 25 | $-0.09 | $0.06 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $0.08 | ||
| Q3 24 | — | $0.10 | ||
| Q2 24 | — | $0.06 | ||
| Q1 24 | — | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $498.9M | $85.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $494.8M | $76.6M |
| Total Assets | $599.9M | $184.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $85.5M | ||
| Q3 25 | $498.9M | $70.7M | ||
| Q2 25 | $286.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $23.2M | ||
| Q3 24 | — | $46.4M | ||
| Q2 24 | — | $8.3M | ||
| Q1 24 | — | $14.4M |
| Q4 25 | — | $76.6M | ||
| Q3 25 | $494.8M | $63.4M | ||
| Q2 25 | $240.1M | $9.5M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $7.1M | ||
| Q3 24 | — | $7.7M | ||
| Q2 24 | — | $5.2M | ||
| Q1 24 | — | $3.7M |
| Q4 25 | — | $184.9M | ||
| Q3 25 | $599.9M | $165.4M | ||
| Q2 25 | $332.3M | $139.5M | ||
| Q1 25 | — | $113.5M | ||
| Q4 24 | — | $96.6M | ||
| Q3 24 | — | $67.3M | ||
| Q2 24 | — | $28.9M | ||
| Q1 24 | — | $26.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $43.5M | $16.3M |
| Free Cash FlowOCF − Capex | $43.5M | $15.8M |
| FCF MarginFCF / Revenue | 65.8% | 25.9% |
| Capex IntensityCapex / Revenue | 0.0% | 0.9% |
| Cash ConversionOCF / Net Profit | 1.67× | 1.34× |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $16.3M | ||
| Q3 25 | $43.5M | $-18.4M | ||
| Q2 25 | $-12.6M | $16.3M | ||
| Q1 25 | — | $20.6M | ||
| Q4 24 | — | $-21.6M | ||
| Q3 24 | — | $38.6M | ||
| Q2 24 | — | $-4.3M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | — | $15.8M | ||
| Q3 25 | $43.5M | $-24.9M | ||
| Q2 25 | $-12.6M | $5.4M | ||
| Q1 25 | — | $5.8M | ||
| Q4 24 | — | $-28.4M | ||
| Q3 24 | — | $38.6M | ||
| Q2 24 | — | $-6.0M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | — | 25.9% | ||
| Q3 25 | 65.8% | -59.3% | ||
| Q2 25 | -38.6% | 12.3% | ||
| Q1 25 | — | 5.8% | ||
| Q4 24 | — | -56.7% | ||
| Q3 24 | — | 55.1% | ||
| Q2 24 | — | -49.4% | ||
| Q1 24 | — | 16.4% |
| Q4 25 | — | 0.9% | ||
| Q3 25 | 0.0% | 15.3% | ||
| Q2 25 | 0.0% | 24.8% | ||
| Q1 25 | — | 15.0% | ||
| Q4 24 | — | 13.4% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 13.8% | ||
| Q1 24 | — | 0.2% |
| Q4 25 | — | 1.34× | ||
| Q3 25 | 1.67× | — | ||
| Q2 25 | — | 11.02× | ||
| Q1 25 | — | 6.93× | ||
| Q4 24 | — | -11.32× | ||
| Q3 24 | — | 14.60× | ||
| Q2 24 | — | -3.09× | ||
| Q1 24 | — | 176.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SLNO
Segment breakdown not available.
TSSI
| Procurement Revenues Segment | $43.2M | 71% |
| System Integration Services Segment | $14.2M | 23% |
| Facilities Segment | $3.5M | 6% |
